Description

Ultibro Brizchailer (glycopyrronium, indacaterol) capsules 110 mcg/50 mcg. №30 with inhaler

Ingredients

Ultibro Brizchailer contains glycopyrronium and indacaterol as active ingredients. Glycopyrronium is an anticholinergic bronchodilator, while indacaterol is a long-acting beta agonist (LABA). These ingredients work together to help relax the muscles in the airways, making it easier to breathe.

Dosage

The recommended dosage of Ultibro Brizchailer is one capsule (110 mcg glycopyrronium/50 mcg indacaterol) to be inhaled once daily using the provided inhaler. It is important to follow the instructions provided by your healthcare provider for the correct usage.

Indications

Ultibro Brizchailer is indicated for the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD). It is not indicated for the treatment of asthma or acute episodes of bronchospasm.

Contraindications

Ultibro Brizchailer is contraindicated in patients with a hypersensitivity to glycopyrronium, indacaterol, or any other components of the product. It should not be used as a rescue medication for acute bronchospasm.

Directions

To use Ultibro Brizchailer, remove one capsule from the blister pack and place it in the inhaler. Inhale the contents of the capsule through the mouthpiece once daily at the same time each day. Do not swallow the capsules.

Scientific Evidence

Studies have shown that the combination of glycopyrronium and indacaterol in Ultibro Brizchailer provides superior bronchodilation compared to either component alone. A randomized controlled trial published in the International Journal of COPD demonstrated that Ultibro Brizchailer improved lung function and quality of life in patients with COPD.

Additional Information

It is important to regularly clean the inhaler device to ensure proper functioning. If you miss a dose of Ultibro Brizchailer, take it as soon as you remember unless it is almost time for your next dose. Do not take a double dose to make up for the missed one.

Pharmacological Effects: Ultibro Brizchailer works by targeting two different pathways in the lungs to provide bronchodilation. Glycopyrronium blocks the action of acetylcholine, a neurotransmitter that causes airway constriction, while indacaterol stimulates beta receptors to relax the airway muscles.

Clinical Trials: In a comparative effectiveness study published in the European Respiratory Journal, Ultibro Brizchailer was found to be more effective in improving lung function and reducing exacerbations in COPD patients compared to other bronchodilator therapies.